[Federal Register Volume 76, Number 8 (Wednesday, January 12, 2011)]
[Notices]
[Page 2130]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-549]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Inhibitors of the
Plasmodial Surface Anion Channel as Antimalarials
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department
of Health and Human Services, is contemplating the grant of an
exclusive patent license to practice the inventions embodied in U.S.
Provisional Patent Application No. 61/083,000, filed July 23, 2008 [HHS
Ref. No. E-202-2008/0-US-01], now expired and PCT Patent Application
No. PCT/US09/50637 [HHS Ref. No. E-202-2008/0-PCT-02] filed July 15,
2009, which published as WO/2010/011537 on January 28, 2010, both
applications entitled ``Inhibitors of the Plasmodial Surface Anion
Channel As Antimalarials,'' and all continuing applications and foreign
counterparts to Microbiotix, Inc., having a place of business in
Worcester, Massachusetts. The patent rights in these inventions have
been assigned to the United States of America.
The prospective exclusive license territory may be ``worldwide'',
and the field of use may be limited to ``prevention and treatment of
malaria in humans.''
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
February 11, 2011 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Kevin W. Chang, PhD, Senior Licensing
and Patenting Manager, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 435-5018; Facsimile: (301) 402-0220; E-
mail: [email protected].
SUPPLEMENTARY INFORMATION: The subject technologies are antimalarial
small molecule inhibitors of the plasmodial surface anion channel
(PSAC), an essential nutrient acquisition ion channel expressed on
human erythrocytes infected with malaria parasites. These inhibitors
were discovered by high-throughput screening of chemical libraries and
analysis of their ability to kill malaria parasites in culture. Two
separate classes of inhibitors were found to work synergistically in
combination against PSAC and killed malaria cultures at markedly lower
concentrations than separately. These inhibitors have high affinity and
specificity for PSAC and have acceptable cytotoxicity profiles.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within thirty
(30) days from the date of this published notice, the NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: January 6, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-549 Filed 1-11-11; 8:45 am]
BILLING CODE 4140-01-P